Skip to main content

Table 1 Overview of patients characteristics

From: Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy

Number of patients

48

Gender

 Male

32

 Female

16

 Unknown Gender

0

Histological subtype

 Adenocarcinoma

23

 Squamous-cell carcinoma

25

Age

 Mean | Median age at diagnosis (years)

64.65 | 64

 Range (years)

44–83

OS

 Deceased

34

 Alive

14

 Range (months)

2.13–78,7

 Median | Mean OS (months)

30.78 | 27.27

PFS

 Deceased

35

 Alive

13

 Range (months)

0.9–31.77

 Median | Mean PFS (months)

9.91 | 5.52

RECIST

 Partial response

18

 Stable disease

11

 Progressive disease

19

PD-L1 status

 TPS > 1%

29

 TPS < 1%

13

Treatment before immunotherapy

 Range (previous therapy lines)

2–7

 Chemotherapy (first-line)

48

 Radiation therapy in addition to chemotherapy

28

ECOG Performance Status

 ECOG = 0

1

 ECOG = 1

33

 ECOG = 2

12

 ECOG > 2

0

Immune-related adverse effects

 Patients affected by irAE

16

 Grade 1 irAE

6a

 Grade 2 irAE

8a

 Grade 3 irAE

7a

  1. aPatients can be affected by multiple ailments